BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 11, 2015
 |  BioCentury  |  Emerging Company Profile

Preventing accumulation

How InFlectis aims to slow down translation of misfolded proteins

InFlectis BioScience S.A.S. is developing preclinical small molecules for Orphan diseases to slow production of misfolded proteins whose accumulation leads to disease. The goal is to turn up one of the three components of the unfolded protein response so that the other two components will be more effective.

The unfolded protein response is a normal response to cellular stress caused when unfolded or misfolded proteins accumulate in the endoplasmic reticulum. The response consists of three pathways: one that slows down protein synthesis, one that up-regulates chaperones that facilitate protein folding, and one that up-regulates proteases to degrade misfolded proteins.

InFlectis' lead compound, IFB-088, keeps the first pathway in an activated state by inhibiting protein phosphatase 1 regulatory subunit 15A (PPP1R15A; GADD34). PPP1R15A is a regulatory subunit of a phosphatase that turns off the protein responsible for activating the pathway.

By blocking this phosphatase, InFlectis hopes to prolong the time in which stressed cells...

Read the full 781 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >